# Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics

> **NCT02611596** · NA · WITHDRAWN · sponsor: **Walter Reed National Military Medical Center**

## Conditions studied

- Silent Myocardial Ischemia
- Type 2 Diabetes

## Interventions

- **DRUG:** Ranolazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02611596
- **Lead sponsor:** Walter Reed National Military Medical Center
- **Sponsor class:** FED
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2018-11
- **Final completion:** 2019-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611596, "Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02611596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*